Estrogen–growth factor crosstalk enhances EGFR phosphorylation and VEGF output, and preclinical studies show synergies when combining anti-estrogens with EGFR inhibitors (fulvestrant with erlotinib/vandetanib), including reduced VEGF secretion and tumor growth suppression [41]. The gene discussed is EGFR; the disease is neoplasm.